PS1-2 CLIP1-LTK: a novel target in non-small cell lung cancer

The discorvery of oncogenic driver has uncovered the pathogenesis of non-small cell lung cancer (NSCLC), and development of corresponding kinase inhibitors has changed treatment strategies and improved survival of patients with druggable oncogenic drivers. However, such oncogenic drivers are not found in 25-40% of lung adenocarcinoma, the most common histological subtype of NSCLC. We established in 2013 a multi-institutional lung cancer genome screening platform, LC-SCRUM-Asia, to identify lung cancer with oncogenic drivers, and to clinically develop molecular targeted therapies.